Last reviewed · How we verify

NCT06793059: SHIELD

Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD)

Recruiting now NA Last updated 10 March 2026
What this trial tests

NA trial testing SHIELD in Aneurysm in 10 participants. Currently enrolling.

Timeline
1 January 2025
Primary endpoint
1 January 2027
1 January 2027

Quick facts

Lead sponsorJacobs institute
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment10
Start date1 January 2025
Primary completion1 January 2027
Estimated completion1 January 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Jacobs institute

Who can join

22 and older, any sex, with Aneurysm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Jacobs Institute is participating in a study designed to collect prospective clinical evidence to evaluate the approved use of the Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with wide-necked intracranial aneurysms

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of SHIELD

Trials testing the same drug.

Other recruiting trials for Aneurysm

Currently open trials in the same condition.

Other Jacobs institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06793059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing